MASP-1/3, Human, mAb 1E2
Three pathways of complement activation have been reported: the antibody-dependent classical pathway, the antibody-independent alternative pathway and the lectin pathway. Activation of each pathway involves formation of serine protease complexes, which results in activation of the central complement component C3. In the lectin pathway, mannose binding-lectin (MBL)-associated serine proteases (MASP) form complexes with polymeric lectin molecules which are involved in pattern recognition. Upon binding of the recognition molecules to carbohydrates on the surface of microorganisms, MASP are converted to their active forms and initiate complement activation. Three types of human MASP have been reported. MASP-1, MASP-2 and MASP-3. MASP-1 appears to cleave the second complement component C2, but not C4. The proteolytic activities of MASP-1 are inhibited by C1-inhibitor. Furthermore MASP-1 has a reactivity profile very similar to that of thrombin. MASP-1 is able to catalyse the formation of cross-linked fibrin. Participation of MASP-1 in cross-linked fibrin clot formation causes release of a chemotactic factor representing a biologically significant activity of MASP-1. The alternative-splicing product from MASP-1 gene is called MASP-3. MASP-1 is associated with smaller MBL oligomers whereas MASP-3 is found on larger oligomers. The substrate of MASP-3 is unknown. The antibody recognizes the heavy chain common to both MASP-1 and MASP-3.
Calculate your ELISA data easily
With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.
Latest Hycult Biotech news
- New Human Complement Pathway AssaysWe are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
- Navigating the pitfalls in complement analysisOur colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis
- NEW Human C3d ELISAWe are happy to introduce our new ELISA (cat.# HK3017) designed to detect human C3d. What sets this assay apart is its utilization of a distinctive neo-epitope capture antibody that selectively targets a specific C3d region of the alpha chain, which is not available in other C3 variants. This way it specifically distinguishes C3d from native C3… Read more: NEW Human C3d ELISA